MCID: ATM050
MIFTS: 24

Autoimmune Thyroid Disease 3

Categories: Genetic diseases

Aliases & Classifications for Autoimmune Thyroid Disease 3

MalaCards integrated aliases for Autoimmune Thyroid Disease 3:

Name: Autoimmune Thyroid Disease 3 54 71 29
Autoimmune Thyroid Disease, Susceptibility to, 3 13
Aitd3 71

Classifications:



External Ids:

OMIM 54 608175
MedGen 40 C1842444
SNOMED-CT via HPO 65 82119001

Summaries for Autoimmune Thyroid Disease 3

UniProtKB/Swiss-Prot : 71 Autoimmune thyroid disease 3: A complex autoimmune disorder comprising two related diseases affecting the thyroid: Graves disease and Hashimoto thyroiditis. In both disorders, thyroid-reactive T-cells are formed and infiltrate the thyroid gland. In Graves disease, the majority of the T-cells undergo a Th2 differentiation and activate B-cells to produce antibodies against the TSH receptor, which stimulate the thyroid and cause clinical hyperthyroidism. In contrast, Hashimoto thyroiditis is characterized by Th1 switching of the thyroid-infiltrating T-cells, which induces apoptosis of thyroid follicular cells and clinical hypothyroidism.

MalaCards based summary : Autoimmune Thyroid Disease 3, also known as autoimmune thyroid disease, susceptibility to, 3, is related to 3mc syndrome 3, and has symptoms including thyroiditis An important gene associated with Autoimmune Thyroid Disease 3 is TG (Thyroglobulin). The drugs Selenium and Bimatoprost have been mentioned in the context of this disorder. Affiliated tissues include thyroid, eye and b cells.

Description from OMIM: 608175

Related Diseases for Autoimmune Thyroid Disease 3

Diseases in the Autoimmune Thyroid Disease 3 family:

Autoimmune Thyroid Disease 2 Autoimmune Thyroid Disease 1
Autoimmune Thyroid Disease 4

Diseases related to Autoimmune Thyroid Disease 3 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 3mc syndrome 3 9.5 TG ZFAT

Symptoms & Phenotypes for Autoimmune Thyroid Disease 3

Clinical features from OMIM:

608175

Human phenotypes related to Autoimmune Thyroid Disease 3:

32
id Description HPO Frequency HPO Source Accession
1 thyroiditis 32 HP:0100646

Drugs & Therapeutics for Autoimmune Thyroid Disease 3

Drugs for Autoimmune Thyroid Disease 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Vet_approved Phase 4,Phase 2,Phase 3 7782-49-2
2
Bimatoprost Approved, Investigational Phase 4,Phase 3 155206-00-1 5311027
3
Ephedrine Approved Phase 4 299-42-3 9294
4
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
5
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
6
Pseudoephedrine Approved Phase 4 90-82-4 7028
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
8
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
9
Dinoprost Investigational Phase 4 551-11-1 5283078
10 Micronutrients Phase 4,Phase 2,Phase 3
11 Trace Elements Phase 4,Phase 2,Phase 3
12 Protective Agents Phase 4,Phase 2,Phase 3
13 Antihypertensive Agents Phase 4,Phase 3
14 Antioxidants Phase 4,Phase 2,Phase 3
15 triamcinolone acetonide Phase 4
16 Prednisolone acetate Phase 4,Phase 2,Phase 3
17 glucocorticoids Phase 4,Phase 2,Phase 3
18 Respiratory System Agents Phase 4
19 Methylprednisolone acetate Phase 4,Phase 2,Phase 3
20 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 3
21 Gastrointestinal Agents Phase 4,Phase 2,Phase 3
22 Nasal Decongestants Phase 4
23 Neuroprotective Agents Phase 4,Phase 2,Phase 3
24 Hematinics Phase 4
25 Tetrahydrozoline Phase 4,Phase 2
26 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
27 Ophthalmic Solutions Phase 4,Phase 2
28 Triamcinolone diacetate Phase 4
29 Triamcinolone hexacetonide Phase 4
30 Hormones Phase 4,Phase 2,Phase 3,Phase 1
31 Oxytocics Phase 4
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
33 Vasoconstrictor Agents Phase 4
34 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
35 Pharmaceutical Solutions Phase 4,Phase 2
36 Anti-Infective Agents Phase 4,Phase 1,Phase 2
37 Immunosuppressive Agents Phase 4
38 Anti-Infective Agents, Local Phase 4
39 Prednisolone hemisuccinate Phase 4,Phase 2,Phase 3
40 Prednisolone phosphate Phase 4,Phase 2,Phase 3
41 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
42 Antiemetics Phase 4,Phase 2,Phase 3
43 Lubricant Eye Drops Phase 4,Phase 2
44 Benzalkonium Compounds Phase 4
45 Autonomic Agents Phase 4,Phase 2,Phase 3
46 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
47 Epoetin alfa Phase 4 113427-24-0
48 Atorvastatin Calcium Phase 4 134523-03-8
49 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
50 Hypolipidemic Agents Phase 4

Interventional clinical trials:

(show all 40)

id Name Status NCT ID Phase Drugs
1 Selenium Supplementation in Pregnancy Unknown status NCT01465867 Phase 4
2 Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism Completed NCT00531713 Phase 4 Triiodothyronine
3 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
4 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
5 Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients Recruiting NCT03004209 Phase 4 Erythropoietin
6 Effects of Statins in Graves' Orbitopathy (GO) in Hypercholesterolemic Patients Not yet recruiting NCT03110848 Phase 4 Atorvastatin;Methylprednisolone
7 Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues Unknown status NCT02155049 Phase 3 bimatoprost 0.03%
8 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3 Rituximab;Saline;Methylprednisolone
9 Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance Completed NCT01295333 Phase 3 the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation;The initiation of LT4 as soon as the first biological signs of hypothyroidism.
10 Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Recruiting NCT03303053 Phase 3 Cholestyramine Powder 4g;Prednisolone;Standard treatment
11 The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Recruiting NCT01579539 Phase 3 Methylprednisolone;Esomeprazole
12 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Not yet recruiting NCT03298867 Phase 3
13 The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Not yet recruiting NCT02422368 Phase 2, Phase 3 Methylprednisolone + ASTED;Methylprednisolone +Placebo
14 The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) Not yet recruiting NCT02393183 Phase 2, Phase 3 ASTED
15 Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01) Terminated NCT00870818 Phase 2, Phase 3 Teplizumab
16 Role of the Microbiome in Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
17 Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention) Completed NCT01551498 Phase 2
18 Teprotumumab Treatment in Patients With Active Thyroid Eye Disease Completed NCT01868997 Phase 2 teprotumumab;normal saline
19 Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2 Methimazole;Rituximab
20 Celecoxib for Thyroid Eye Disease Recruiting NCT02845336 Phase 2 Celecoxib;artificial tears
21 IL-2 in Refractory Autoimmune Encephalitis Not yet recruiting NCT02714959 Phase 1, Phase 2 Proleukin
22 Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment Terminated NCT00288522 Phase 2 Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
23 TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease Completed NCT00335062 Phase 1
24 A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects Completed NCT01581463 Phase 1 Liothyronine, Sodium
25 Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study Recruiting NCT02760056 Phase 1 Liothyronine sodium;Placebo
26 Comparative Study of Different I-131 Doses in Graves' Disease Unknown status NCT02114619 Low dose of I-131;Intermediate dose;High dose
27 Maternal Autoimmune Thyroid Disease and Fetal Thyroxin Completed NCT01528904
28 Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients Completed NCT01876329
29 Low Level Laser Therapy for Autoimmune Thyroiditis Completed NCT02240563
30 T and B Cells in Graves' Orbitopathy Completed NCT03195296
31 Profiling Urticaria for the Identification of Subtypes Completed NCT01637116
32 Cumulative Live Birth Rates in Patients With Repeated Implantation Failure (RIF) Undergoing Preimplantation Genetic Screening (PGS ) Completed NCT03001648
33 Fetal Thyroid Ultrasound And Fetal Thyroid Hormones Recruiting NCT02017080
34 HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome Recruiting NCT01931293
35 Prevalence of Thyroid Function Abnormalities in HIV-infected Patients: State of Play in 2012 Recruiting NCT03149354
36 B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease Recruiting NCT02316691
37 HIFU vs RAI in the Relapsed Graves' Disease Recruiting NCT03013257
38 DNA Methylation and Autoimmune Thyroid Diseases Active, not recruiting NCT02491567
39 Serum Auto-Antibodies in Neurological Diseases Enrolling by invitation NCT00704626
40 Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment Terminated NCT01893450 Methimazole;Bromocriptine;Pentoxifylline

Search NIH Clinical Center for Autoimmune Thyroid Disease 3

Genetic Tests for Autoimmune Thyroid Disease 3

Genetic tests related to Autoimmune Thyroid Disease 3:

id Genetic test Affiliating Genes
1 Autoimmune Thyroid Disease 3 29

Anatomical Context for Autoimmune Thyroid Disease 3

MalaCards organs/tissues related to Autoimmune Thyroid Disease 3:

39
Thyroid, Eye, B Cells, T Cells, Fetal Thyroid

Publications for Autoimmune Thyroid Disease 3

Variations for Autoimmune Thyroid Disease 3

ClinVar genetic disease variations for Autoimmune Thyroid Disease 3:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 ZFAT ZFAT1, IVS9, A-T single nucleotide variant risk factor
2 TG NM_003235.4(TG): c.5995C> T (p.Arg1999Trp) single nucleotide variant risk factor rs2076740 GRCh37 Chromosome 8, 133984058: 133984058
3 TG NM_003235.4(TG): c.2200T> G (p.Ser734Ala) single nucleotide variant risk factor rs180223 GRCh37 Chromosome 8, 133900252: 133900252
4 TG NM_003235.4(TG): c.3082A> G (p.Met1028Val) single nucleotide variant risk factor rs853326 GRCh37 Chromosome 8, 133909974: 133909974
5 TG NM_003235.4(TG): c.-1623A> G single nucleotide variant risk factor rs180195 GRCh37 Chromosome 8, 133877623: 133877623

Expression for Autoimmune Thyroid Disease 3

Search GEO for disease gene expression data for Autoimmune Thyroid Disease 3.

Pathways for Autoimmune Thyroid Disease 3

GO Terms for Autoimmune Thyroid Disease 3

Sources for Autoimmune Thyroid Disease 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....